Jan 19, 2022, SEB Healthcare Seminar
Jan 20, 2022, Redeye Fight Cancer Seminar
Mar 15-17, 2022, Carnegie Healthcare Seminar
Mar 23, 2022, Swiss Nordic Bio Conference, Zürich, Switzerland
BT-001 publication in JITC, Jan 20, 2022 > Link
Listen to a panel discussion with CEO Martin Welschof: “Developing a portfolio of first-in-class immuno-oncology antibodies” arranged by the Antibody Society and Sofinnova Partners, Nov 23, 2021 > Link
Redeye CEO interview on the recent positive BI-1206 data > Link
BI-1206 KOL event, Dec 17, 2021 > Link
BioStock Status Report on BioInvent, Nov 26, 2021 (In Swedish) > Link
BioInvent’s strategy is to leverage its expertise in immunology, cancer biology and antibody biology to develop cancer immunotherapies to improve the quality of life for cancer patients. This is accomplished through collaborations with pharmaceutical companies, academic research groups, networks of clinical specialists and research foundations. The goal is to create value for the Company’s shareholders based on successful drug development and subsequent revenue streams from existing and future commercial partners.
Our tools for successful drug development
In an automated process, we select optimal antibodies for new drug candidates from our own antibody library – one of the largest in the world.
Our unique and patented screening-platform has the advantage of simultaneously identifying disease-associated targets and antibodies that bind to them.